Eli Lilly’s obesity pill remains a viable rival to Novo’s oral Wegovy despite data that underwhelmed investors August 24, 2025 John Cooper Global Market No comments yet **Eli Lilly’s Orforglipron: A Game-Changer in the Diabetes Treatment market?** The diabetes treatment market is heating up, with pharmaceutical giant… Read more
Novo Nordisk offers diabetes drug Ozempic for less than half the price for cash-paying U.S. patients August 18, 2025 John Cooper Global Market No comments yet **Novo Nordisk’s Ozempic Pricing Strategy: A Game-Changer for Investors?** **market Context: A Shift in Healthcare Affordability** The healthcare in… Read more
Denmark’s Economy Runs on Novo. Will the Drugmaker’s Troubles Slim It Down? August 3, 2025 John Cooper Global Market No comments yet **Denmark’s Economic Star Loses Luster: Novo Nordisk’s Struggle in the US Weight-Loss Market** **Europe’s Economic Bright Spot Falters** Denmark has long been touted as one of the few European count… Read more
Novo Falls by Record as Wegovy Slumps and Insider Named CEO July 29, 2025 John Cooper Global Market No comments yet **Novo Nordisk Shakes Up Leadership Amidst Slumping Weight-Loss Drug Sales** **New CEO Takes the Helm Amidst Market Turmoil** In a move aimed at revitalizing the company’s fortunes, Novo Nordisk A/S… Read more
ETH to Lead BTC Over Next 6 Months, Says Galaxy CEO July 26, 2025 John Cooper Crypto News No comments yet **Ethereum Poised to Outshine Bitcoin: Novogratz’s Bold Prediction** As the cryptocurrency market continues to experience volatility, Galaxy CEO Mike Novogratz has made a striking prediction: Ethereu… Read more